Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations

BMC Cancer

Volumn 9, Issue , 2009, Pages 387-

  Preto, Ana ^a,b   Gonçalves, Joana ^a   Rebocho, Ana P ^a   Figueiredo, Joana ^a   Meireles, Ana M ^a   Rocha, Ana S ^a   Vasconcelos, Helena M ^a   Seca, Hugo ^a   Seruca, Raquel ^a,c   Soares, Paula ^a,c   Sobrinho Simões, Manuel ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BROXURIDINE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN MCL 1; SORAFENIB;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRAIN 8505C; CELL STRAIN C643; CELL STRAIN TPCI; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; NICK END LABELING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THYROID CANCER; WESTERN BLOTTING;

EID: 70749088911     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-387     Document Type: Article

References (37)

1. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sobrinho-Simoes M. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004, 444:572-576. 10.1007/s00428-004-1018-0, 15095090.
2. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404. 10.1210/jc.2003-030838, 14602780.
3. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580. 10.1038/sj.onc.1206706, 12881714.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
5. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003, 1653:25-40.
6. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005, 24:3459-3471. 10.1038/sj.onc.1208544, 15735667.
7. Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 2007, 26:1056-1066. 10.1038/sj.onc.1209861, 16924241.
8. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63:5198-5202.
9. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 2003, 278:42409-42418. 10.1074/jbc.M308709200, 12917419.
10. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K, Kawakami Y. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004, 23:6031-6039. 10.1038/sj.onc.1207812, 15208655.
11. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298. 10.1038/sj.onc.1207785, 15208680.
12. Christensen C, Guldberg P. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 2005, 24:6292-6302. 10.1038/sj.onc.1208758, 16007203.
13. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006, 66:999-1006. 10.1158/0008-5472.CAN-05-2720, 16424035.
14. Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 2008, 214:320-327. 10.1002/path.2295, 18098337.
15. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007, 6:1785-1792. 10.1158/1535-7163.MCT-06-0595, 17575107.
16. Liu D, Liu Z, Condouris S, Xing M. BRAF V600E Maintains Proliferation, Transformation and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells. J Clin Endocrinol Metab 2007, 92:2264-2271. 10.1210/jc.2006-1613, 17374713.
17. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006, 12:1623-1629. 10.1158/1078-0432.CCR-05-2378, 16533790.
18. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 2007, 6:1070-1078. 10.1158/1535-7163.MCT-06-0449, 17363500.
19. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006, 12:1785-1793. 10.1158/1078-0432.CCR-05-1729, 16551863.
20. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. 10.1016/S0092-8674(04)00215-6, 15035987.
21. Meireles AM, Preto A, Rocha AS, Rebocho AP, Maximo V, Pereira-Castro I, Moreira S, Feijao T, Botelho T, Marques R. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007, 17:707-715. 10.1089/thy.2007.0097, 17725429.
22. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93:4331-4341. 2582569, 18713817, 10.1210/jc.2008-1102.
23. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001, 8:219-225. 10.1677/erc.0.0080219, 11566613.
24. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844. 10.1038/nrd2130, 17016424.
25. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007, 96:16-20. 2360215, 17179987, 10.1038/sj.bjc.6603520.
26. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003, 22:9192-9196. 10.1038/sj.onc.1207061, 14668801.
27. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007, 26:3100-3112. 10.1038/sj.onc.1210392, 17496909.
28. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308. 10.1038/nrc2109, 17384584.
29. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 2006, 147:1014-1019. 10.1210/en.2005-0280, 16254036.
30. Rocha AS, Paternot S, Coulonval K, Dumont JE, Soares P, Roger PP. Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell 2008, 19:4814-4825. 2575166, 18799615, 10.1091/mbc.E08-06-0617.
31. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98:326-334.
32. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109. 10.1158/0008-5472.CAN-04-1443, 15466206.
33. Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells. Oncogene 2006, 26:1056-1066. 10.1038/sj.onc.1209861, 16924241.
34. Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford-Thomas D, Bond JA. Evidence for a telomere-independent "clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol Cell Biol 2000, 20:5690-5699. 86042, 10891505, 10.1128/MCB.20.15.5690-5699.2000.
35. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006, 66:1611-1619. 10.1158/0008-5472.CAN-05-0808, 16452220.
36. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869. 10.1038/sj.onc.1208841, 16007148.
37. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26:4714-4719. 2653134, 18541894, 10.1200/JCO.2008.16.3279.